Impact of Baseline Retinal Nonperfusion and Macular Retinal Capillary Nonperfusion on Outcomes in the COPERNICUS and GALILEO Studies.

[1]  D. Pieramici,et al.  Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE. , 2018, Ophthalmology.

[2]  N. Lois,et al.  Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion. , 2018, Survey of ophthalmology.

[3]  J. Haller,et al.  Integrated results from the COPERNICUS and GALILEO studies , 2017, Clinical ophthalmology.

[4]  A. Wenzel,et al.  Individualized Ranibizumab Regimen Driven by Stabilization Criteria for Central Retinal Vein Occlusion: Twelve-Month Results of the CRYSTAL Study. , 2016, Ophthalmology.

[5]  Rishi P. Singh,et al.  Central retinal vein occlusion: modifying current treatment protocols , 2016, Eye.

[6]  N. Waheed,et al.  Optical Coherence Tomography Angiography of Retinal Vein Occlusion. , 2016, Developments in ophthalmology.

[7]  Marco Rispoli,et al.  CAPILLARY NETWORK ANOMALIES IN BRANCH RETINAL VEIN OCCLUSION ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY , 2015, Retina.

[8]  U. Schmidt-Erfurth,et al.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study. , 2014, American journal of ophthalmology.

[9]  C. Wykoff,et al.  RANIBIZUMAB IN PREPROLIFERATIVE (ISCHEMIC) CENTRAL RETINAL VEIN OCCLUSION: The Rubeosis Anti-VEGF (RAVE) Trial , 2014, Retina.

[10]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. , 2014, Ophthalmology.

[11]  J. Haller,et al.  Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. , 2013, American journal of ophthalmology.

[12]  Y. Ogura,et al.  VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study , 2013, British Journal of Ophthalmology.

[13]  K. Park,et al.  Baseline Characteristics and Risk Factors of Retinal Vein Occlusion: A Study by the Korean RVO Study Group , 2013, Journal of Korean medical science.

[14]  M. Figueroa,et al.  Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion , 2012, Drugs.

[15]  J. Haller,et al.  Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. , 2012, Ophthalmology.

[16]  G. Yancopoulos,et al.  Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab , 2012, Angiogenesis.

[17]  M. Laouri,et al.  The burden of disease of retinal vein occlusion: review of the literature , 2011, Eye.

[18]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[19]  Jean-Pierre Hubschman,et al.  Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. , 2010, Ophthalmology.

[20]  P. Mitchell,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[21]  S. Hayreh,et al.  Relative afferent pupillary defect in central retinal vein occlusion. , 1986, Ophthalmology.

[22]  S. Badrinath,et al.  Central retinal vein occlusion. , 1984, Indian journal of ophthalmology.

[23]  Gabriel Coscas,et al.  Optical Coherence Tomography Angiography in Retinal Vein Occlusion: Evaluation of Superficial and Deep Capillary Plexa. , 2016, American journal of ophthalmology.

[24]  U. Schmidt-Erfurth,et al.  Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. , 2014, Ophthalmology.

[25]  S. Hayreh,et al.  Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase , 2004, Graefe's Archive for Clinical and Experimental Ophthalmology.

[26]  A. Hillis,et al.  Baseline and early natural history report. The Central Vein Occlusion Study. , 1993, Archives of ophthalmology.

[27]  Classification of diabetic retinopathy from fluorescein angiograms. ETDRS report number 11. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.